Metabolism of 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 in humans.

Tritium-labeled 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 was administered by intravenous injection into humans. The initial half-life in plasma was determined to be about 3 min. About 35% of the injected radioactivity was excreted in the urine and about 55% in the feces. Twenty-three urinary metabolites were identified. The metabolites included beta-oxidized and omega-oxidized products as well as metabolites in which the 9-methylene group had been biotransformed.